We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
The Lilly train keeps on rolling thanks to Mounjaro and Zepbound. And there's more growth to be had
Originally published by CNBC. Summary and curation by DutyStation News.
📰 Related Stories
🏛️ Politics
Alaska Senate election: Governor orders probe of alleged effort to recruit second Dan Sullivan
CNBC1h ago
🏛️ Politics
Some investors have midterm election jitters. Here’s what history shows about stocks
CNBC1h ago
🏛️ Politics
European Central Bank President Lagarde to step down early
Al Jazeera2h ago
🏛️ Politics
Why US Sports Owners Spend Millions on Politics
Al Jazeera2h ago
🏛️ Politics
The Justice Department has fewer attorneys. The workload didn’t get the memo.
Federal News Network2h ago
🏛️ Politics
2026 Midterm Election Ballot Measures: What Races We’re Watching
NYT US News2h ago